california and amsterdam
CENTURY CITY, California and AMSTERDAM, December 1, 2011 -
Original Live Stage Spectacular Combining Exceptional Ice Skating, Aerial Arts, Puppetry and Film To Debut In 2012 With Rollout In More Than 30 Countries
It's the dawn of a new age as Twentieth Century Fox Consumer Products and Stage Entertainment Touring Productions today announce the launch of Ice Age Live! A Mammoth Adventure, a completely original live entertainment spectacular.
IRVINE, California and AMSTERDAM, October 24, 2011 -
Agendia, an innovative molecular diagnostics company, today announced that its supervisory board of directors has appointed David Macdonald as chief executive officer.
IRVINE, California and AMSTERDAM, October 3, 2011 -
Agendia, an innovative molecular cancer diagnostics company, today announced that the company successfully completed a recent, routine inspection of its Irvine, California-based laboratories by the US Food and Drug Administration (FDA).
IRVINE, California and AMSTERDAM, September 19, 2011 -
- Peer-Reviewed Article Notes That Multi-Gene Subtyping Profile Provides Deeper Insight Into Breast Cancer
Agendia, an innovative molecular cancer diagnostics company, today announced that a published report highlighting the development and validation of its 80-gene BluePrint breast cancer profile was published online in Breast Cancer Research and Treatment, a peer-reviewed publication.
IRVINE, California and AMSTERDAM, August 10, 2011 -
Panel's Recommendations Reinforce Clinical Value of Tests Such as BluePrint
Agendia, a commercial-stage molecular cancer diagnostics company, today announced that the 12th St.
More News
- Agendia Receives 1.27 Million in Funding from the EU’s Seventh Framework Programme
- Agendia Hires David Macdonald as Chief Operating Officer, Mark Willig as Executive VP of North American Sales, and Doug Bradley as Vice President of Global Marketing
- Agendia Receives Fifth FDA Clearance for Industry Leading MammaPrint(R) Assay
- Second Independent Validation Study of ColoPrint Selected for Oral Presentation and Press Conference at ASCO GI in January 2011
- 178m US Lives Covered by Adding Humana Contract for FDA-Cleared Breast Cancer Test
- Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
- Agendia and Ferrer inCode Expand MammaPrint(R) Distribution Agreement to Latin America
- New Service to Provide Breast Cancer Molecular Subtyping
- 12 Cancer Drugs Tested, 20 Leading U.S. Cancer Centers Involved
- Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
- FDA Broadens Clearance for Agendia's MammaPrint(R)
- Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium
- Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint(R)
- Agendia to Present at BioCentury’s Future Leaders in the Biotech Industry Conference
